Rituximab (Synonyms: Anti-Human CD20 type I, Chimeric Antibody)

Name: Rituximab
Brand: MedChemExpress
SKU: HY-P9913
Rating: 5.0 (7 reviews)

Cat. No.: HY-P9913 Purity: 98.53%: FAQs
Data Sheet
SDS

COA
Technical Support

Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.

For research use only. We do not sell to patients.

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	Get quote
200 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 7 publication(s) in Google Scholar

Other Forms of Rituximab:

Rituximab (anti-CD20) Get quote

7 Publications Citing Use of MCE Rituximab

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products:

View All Isoforms

RDC Peptide RDC Antibody RDC Bifunctional Chelator RDC Linker Other

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species

Chimeric

IC₅₀ & Target

RDC Antibody

In Vitro

Rituximab inhibits the proliferation of stimulated human B cells, which is associated with a relative increase of B cells with an activated naive phenotype. Aside from this population shift, there are no major changes in phenotype or cytokine profile of the various B-cell subsets. B cells stimulated in the presence of rituximab induces stronger T-cell proliferation, compared to B cells stimulated in the absence of rituximab^[1]. All lymphoma cells tested are equally sensitive to antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-mediated phagocytosis of tumor cells, and rituximab-induced apoptosis. Rituximab induces high CDC killing of follicular lymphoma cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cures 100% of the animals. Depletion of either NK cells or neutrophils or both in tumor-injected animals does not affect the therapeutic activity of the drug. Similarly, rituximab is able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

143470.00

CAS No.

174722-31-7

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Rituximab]

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Format

Human IgG1 kappa

Biological Activity

Rituximab has a significant ADCC effect on Raji cells in a dose-dependent manner.The EC₅₀ for this effect is 6.56 and 3.25 ng/mL.

Purity & Documentation

Purity: 99.85%

Select Batch:

Data Sheet (262 KB) SDS (251 KB)

COA (291 KB)

Inhibitory Antibodies User Guide (602 KB)

References

[1]. Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12(2):341-50. [Content Brief]

[2]. Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101(3):949-54. [Content Brief]

[3]. Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99(3):1038-43. [Content Brief]

Cell Assay	A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cures 100% of the animals. Depletion of either NK cells or neutrophils or both in tumor-injected animals does not affect the therapeutic activity of the drug. Similarly, rituximab is able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	C57BL/6 mice (8-10 wk of age) are inoculated 8×10³ EL4-CD20⁺ cells in 200 μL of saline by tail vein injection. In parallel groups of mice, 150 g of rituximab, murine anti-CD20 IgG2a Ab 1F5, or control anti-human IL-2R Ab daclizumab in 300 μL of saline, or saline only is inoculated i.p. 24 h later^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12(2):341-50. [Content Brief] [2]. Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101(3):949-54. [Content Brief] [3]. Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99(3):1038-43. [Content Brief]

Rituximab Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Rituximab174722-31-7Anti-Human CD20 type I, Chimeric AntibodyRadionuclide-Drug Conjugates (RDCs)CD20Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Rituximab (Synonyms: Anti-Human CD20 type I, Chimeric Antibody)

Customer Review

Other Forms of Rituximab:

Rituximab Related Antibodies

7 Publications Citing Use of MCE Rituximab

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Rituximab Related Antibodies

Rituximab Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report